Abstract
Background Prostate cancer incidence and mortality are expected to increase considerably in the near future in Thailand. There is thus an urgent need to establish prevention measures, such as screening, to reduce the increasing burden of prostate cancer in Thailand.
Methods Using data from several sources including the Songkhla Cancer Registry and the census data from Thailand, we conducted a simulation analysis to assess the potential impact of screening on the incidence and mortality of prostate cancer among 10 million males aged 50 to 70 of 1960 birth cohort from Songkhla, Thailand. We assumed 4 different scenarios, including no screening, 15%, 60% and 100% screening uptakes of the prostate-specific antigen test. Furthermore, stage distribution of prostate cancer was assumed based on two major prostate cancer screening trials: European Randomized Study of Screening for Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The number of prostate cancer cases was projected using an age-period-cohort model approach, accounting for the expected excess of cases due to screening. Deaths from prostate cancer were then projected using survival probabilities from Songkhla and the United States. Case fatality ratios (CFRs) were also computed.
Results Prostate cancer incidence increased with screening, as expected, with a shift of the stage distribution toward earlier stages, but mortality from prostate cancer decreased with higher screening uptake. Assuming 1.71 excess risk of cases due to screening and stage distribution from the ERSPC trial, we projected an increase of over 7,000 localized cases under 100% screening uptake, while the cases in advanced stages decreased from 4,046 (no screening) to 96 under 100% screening uptake. The number of deaths were reduced by 82% under 100% screening uptake compared to no screening. The CFR also decreased from 0.42 (no screening) to 0.05 (100% screening).
Conclusion Screening for prostate cancer could substantially reduce the number of prostate cancer cases in advanced stages and prostate cancer deaths. Although the net benefit depends on the assumed survival rates under screening, which could vary depending on the quality of the implementation, screening would contribute to reducing the escalating burden of prostate cancer in Thai population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Alvarez was supported by the Thomas Francis, Jr Endowment Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Since this study involves only population-based, de-identified data with no personal information included, it was classified as exempt by the institutional review board at the University of Michigan. This exemption status is based on adherence to data privacy standards, including the removal of all personally identifiable information, ensuring compliance with institutional and regulatory requirement for secondary data analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- BRFSS
- Behavioral Risk Factor Surveillance System
- CFR
- Case Fatality Ratios
- DRE
- Digital Rectal Examination
- ERSPC
- European Randomized Study of Screening for Prostate Cancer
- PLCO
- Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
- PSA
- Prostate Specific-Antigen
- USPSTF
- US Preventive Services Task Force
